Gabapentin
Ordering Recommendation
Optimize drug therapy and monitor patient adherence.
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Mon, Wed-Sat
Reported
1-4 days
New York DOH Approval Status
Specimen Required
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Plain red. Also acceptable: Lavender (K2 or K3EDTA) or Pink (K2EDTA).
Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.2 mL)
Refrigerated.
Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
After separation from cells: Ambient: 1 month; Refrigerated: 1 month; Frozen: 2 months
Reference Interval
Effective November 18, 2013
Therapeutic Range | 2-20 µg/mL |
Toxic | Not well established |
Interpretive Data
Pharmacokinetics of gabapentin vary widely among patients, particularly those with compromised renal function. Adverse effects may include somnolence, dizziness, ataxia, and fatigue.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Note
Hotline History
CPT Codes
80171
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
0090057 | Gabapentin | 9738-6 |
Aliases
- Gabapentin, Free
- Gabarone
- Neurontin